Drugs / Farletuzumab
Trials 7
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 13 trials | ||||||
| Phase 1 | NCT01049061 | Jan 2010 → Jan 2013 | neoplasm | Eisai Inc. | Completed | No outcome recorded |
| Phase 1 | NCT01004380 | Nov 2009 → Aug 2012 | ovarian epithelial tumor | Morphotek | Completed | No outcome recorded |
| Phase 1 | NCT00428766 | Jun 2005 → Dec 2007 | malignant epithelial tumor of ovary | Morphotek | Completed | No outcome recorded |
| Phase 24 trials · 1 missed | ||||||
| Phase 2 | NCT02289950 | Mar 2015 → May 2019 | — | Eisai Inc. | Completed | Missed primary |
| Phase 2 | NCT01203618 | Feb 2011 → Jun 2013 | non-functioning pituitary adenoma | Morphotek | Withdrawn | No outcome recorded |
| Phase 2 | NCT01018563 | Jan 2010 → Mar 2013 | malignant epithelial tumor of ovary | Morphotek | Terminated | No outcome recorded |
| Phase 2 | NCT00318370 | May 2006 → Feb 2010 | fallopian tube cancer, ovarian cancer, peritoneal neoplasm | Morphotek | Completed | No outcome recorded |
| Comparator or background therapy3 trials | ||||||
| Phase 2 | NCT01218516 Comparator | Jun 2011 → Dec 2012 | lung adenocarcinoma | Morphotek | Completed | No outcome recorded |
| Phase 2 | NCT00738699 Comparator | Sep 2008 → Dec 2011 | ovarian cancer | Morphotek | Terminated | No outcome recorded |
| Phase 3 | NCT00849667 Comparator | Apr 2009 → Dec 2012 | ovarian cancer | Morphotek | Terminated | No outcome recorded |
News releases announcing trial results or a regulatory action · 2
| Date | Issuer | Release |
|---|---|---|
| 2013-01-11 | Eisai Inc. | Results EISAI ANNOUNCES RESULTS OF PHASE Ⅲ STUDY OF ANTICANCER AGENT FARLETUZUMAB IN PATIENTS WITH RELAPSED PLATINUM-SENSITIVE OVARIAN CANCER eisai.com ↗
Preliminary results showed that the trial did not meet the pre-specified statistical criteria for significant progression-free survival (PFS), the study’s primary endpoint. |
| 2008-04-16 | Eisai Inc. | Regulatory European Regulatory Agency Grants Orphan Status to Morphotek®'s FARLETUZUMAB (MORAb-003) and MORAb-009 Upon marketing authorization orphan status would provide for ten years of market exclusivity in the European Union for both investigational treatments eisai.com ↗ |
All press releases naming this drug 7 releases
Evidence & citations 7 cited values
Every value below carries the sentence it was read from. 12 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | farletuzumab | “A phase I study of farletuzumab, a humanized anti-folate receptor α monoclonal antibody, in patients with solid tumors.” PMID 25380636 ↗ Nov 2014 |
| Known as | Farletuzumab (MORAb-003) | “Farletuzumab (MORAb-003)” NCT01004380 ↗ |
| Known as | MORAb 003 | “Farletuzumab (MORAb 003)” NCT02289950 ↗ |
| Action | Inhibit | “Folate receptor alpha inhibitor” CHEMBL1743016 ↗ |
| Modality | Monoclonal antibody | “Farletuzumab is a humanized monoclonal antibody to folate receptor-α” PMID 23474348 ↗ Mar 2013 |
| Route | Intravenous | “administered by intravenous (IV) infusion” NCT00738699 ↗ |
| Target | FOLR1 | “Folate receptor alpha inhibitor” CHEMBL1743016 ↗ |